REGN
Regeneron Pharmaceuticals, Inc.
September 30, 2026 · after-hours
- Rarity
- 1.23
- Peak move
- −4.10%
- Float cap
- $77.1B
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates target eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. It provides these medicines to patients and medical professionals.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
4 events · 1 from SEC or newswire · 1 timed with the move- Timed with the move
executive_appointmentRegeneron granted CEO Leonard Schleifer and CSO George Yancopoulos one-time performance share unit awards on September 24, 2026, capped at 2,700,000 and 2,900,000 PSUs respectively, replacing annual equity awards until 2036.
SEC8-K 0001104659-26-112340 clinical_readoutRegeneron reported initial study results for ubamatamab (MUC16xCD3) showing a high rate of durable responses in patients with advanced low-grade serous ovarian cancer.
clinical_readoutRegeneron reported Phase 2 COURAGE trial results showing trevogrumab prevented 70% of muscle loss associated with semaglutide treatment in a predefined MRI substudy.
major_contractRegeneron and Sanofi expanded their global alliance to include REGN20423, a clinical-stage long-acting IL-13 antibody, plus a long-acting IL-4xIL-13 bispecific and two preclinical antibodies.